Advances in the molecular mechanisms underlying progestin resistance in endometrial cancer
Fundamental Research, ISSN: 2667-3258
2023
- 2Citations
- 1Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations2
- Citation Indexes2
- CrossRef2
- Captures1
- Readers1
Review Description
The incidence of endometrial cancer (EC) has been on the rise, with a notable increase observed in younger female population. Approximately 80% of EC patients are associated with endometrial hyperplasia, a condition characterized by excessive stimulation from unopposed estrogen. Progestin, as a natural antagonist of estrogen, is recommended for patients with fertility conservation requirements. However, some patients may exhibit insensitivity to progestin treatment, and those with comorbidities such as obesity and diabetes may experience suboptimal therapeutic effects. To improve the efficacy of progestin treatment and address the fertility needs of patients, it is imperative to elucidate the underlying mechanisms of progestin insensitivity in EC. In this review, we explore the role of progestin in EC and its clinical effectiveness. We discuss the factors contributing to progestin insensitivity, highlight recent advancements in research aimed at enhancing treatment sensitivity, and propose potential avenues for future investigation.
Bibliographic Details
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know